Quantcast

Latest Targeted therapy Stories

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-28 23:19:13

Tozaride Targeted Therapy Shows Tumor Reduction in Animal Model Somerville, Massachusetts (PRWEB) May 28, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that its Tozaride targeted pancreatic cancer therapy has been selected for abstract publication at the 2014 ASCO meeting in Chicago, IL, May 30-June 4. The abstract - e15224: Effect of rhenium Re188-P2045 (Tozaride) on tumor growth in the AR42J rat pancreatic tumor xenograft nude mouse model - is available online at...

2014-05-28 08:31:13

Strategic dealmaker to advance Epic's leading circulating tumor cell (CTC) technology as a rapid and non-invasive platform for on-label, marketed companion diagnostics SAN DIEGO, May 28, 2014 /PRNewswire/ -- Epic Sciences announced today the appointment of Jason Adams as vice president of business development. Mr. Adams has more than 15 years of experience in biotech and diagnostic business development. Mr. Adams has specialized in negotiating and structuring complex revenue...

2014-05-22 23:01:48

Offers Potential New Therapy for Difficult-to-Treat Triple Negative Breast Cancer Philadelphia, PA (PRWEB) May 22, 2014 A study from the Department of Biochemistry and Molecular Biology at Drexel University College of Medicine offers a potential new therapy for difficult-to-treat breast cancers. A team of investigators discovered that targeting a specific enzyme can kill triple-negative breast cancer cells, but spare non-tumor cells as well. The study is currently available in the online...

2014-05-18 23:01:09

RnRMarketResearch.com offers "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" research report in its store. Dallas, TX (PRWEB) May 18, 2014 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 research report says, thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion...

2014-05-16 12:27:57

RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS, May 16, 2014 /PRNewswire-iReach/ -- "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately...

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias...

2014-04-29 12:27:59

Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists' are optimistic that Boehringer Ingelheim's second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) Gilotrif/Giotrif will offer efficacy and delivery advantages over currently available agents for the second- and...

2014-04-23 08:31:41

- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative...

2014-04-22 12:31:30

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/gastrointestinal_stromal_tumor_gist_global_clinical_trials_review.html Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Gastrointestinal Stromal Tumor (GIST) Global...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related